Jaguar Health, Inc. is exploring strategic alternatives to enhance shareholder value as it prepares for a New Drug Application for a crofelemer-based treatment aimed at rare intestinal failure diseases. The company is considering options such as mergers, acquisitions, and partnerships with both biotech and non-biotech companies. CEO Lisa Conte has reiterated the company’s dedication to its crofelemer development program, which seeks to offer solutions for patients with intestinal failure, a condition that necessitates long-term nutritional support and presents significant complications. The global market for treatments, including those for microvillus inclusion disease, is expected to grow significantly. Crofelemer has shown promise in reducing the need for parenteral support in trials, and upcoming findings will be presented at the ESPGHAN Annual Meeting.
Is Jaguar Health Exploring Strategic Alternatives?
